Johnson & Johnson reached a $5.5 billion settlement on 28 July 2026, resolving approximately 69,000 US lawsuits consolidated in federal court in New Jersey, with plaintiffs alleging that talc-based baby powder and related products caused ovarian cancer [Brief - 2026-09-19]. This resolution brings a degree of legal closure to one of the largest product liability disputes in the company's history. The settlement figure represents a defined financial obligation that has been disclosed in recent reporting periods, and its terms were confirmed through federal court proceedings in the New Jersey jurisdiction [Brief - 2026-09-11].
For the trailing twelve months ending 28 June 2026, Johnson & Johnson recorded revenue of approximately $97.9 billion, representing year-over-year growth of 6.6%. Net income over the same period was $21.0 billion, with a net margin of 21.5% and a gross margin of 67.9%. Operating margin stood at 27.4%. Earnings per share declined 0.87% year-over-year. The company held $20.4 billion in cash against total debt of $49.0 billion, resulting in a net debt position. The trailing price-to-earnings ratio was reported at 31.5x [SEC 10-Q - JNJ - 2026-06-28].
Insider activity in September 2026 comprised four transactions, with a net direction of selling and a net disposed value of approximately $9.2 million [SEC Form 4 - JNJ - 2026-09]. On the institutional side, five prominent funds each opened new positions in JNJ during the most recent 13F reporting period: Citadel, AQR Capital, Millennium, Bridgewater, and Soros Fund Management all initiated holdings [SEC 13F - Citadel - Q2 2026] [SEC 13F - AQR Capital - Q2 2026] [SEC 13F - Millennium - Q2 2026] [SEC 13F - Bridgewater - Q2 2026] [SEC 13F - Soros Fund Mgmt - Q2 2026]. These simultaneous initiations across multiple large institutional managers represent the primary trigger for this report.
The prevailing macroeconomic environment shows the 10-year US Treasury yield at 5.18% and the 2-year yield at 4.87%, reflecting a normal yield curve configuration [FRED DGS10] [FRED DGS2]. This rate environment affects the cost of carrying JNJ's $49.0 billion total debt load and the discount rates applied to long-duration cash flows across the healthcare sector broadly.